{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:20:02Z","timestamp":1791667202371,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04384-1","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:22:48Z","timestamp":1760444568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of anti-CGRP monoclonal antibodies on treatment satisfaction and quality of life in patients with resistant migraine: a retrospective real-world study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-7322","authenticated-orcid":false,"given":"Laura","family":"Cardona-Roca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5291-9831","authenticated-orcid":false,"given":"Carlos","family":"Segu\u00ed-Solanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5184-7481","authenticated-orcid":false,"given":"Manuel","family":"Cano-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4420-1631","authenticated-orcid":false,"given":"Alba","family":"Sosa-Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9611-8796","authenticated-orcid":false,"given":"Nuria","family":"Almendros-Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1288-8046","authenticated-orcid":false,"given":"Nuria Rudi","family":"Sola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"4384_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40001-022-00716-w","volume":"27","author":"H Sevivas","year":"2022","unstructured":"Sevivas H, Fresco P. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res. 2022;27:86. https:\/\/doi.org\/10.1186\/s40001-022-00716-w.","journal-title":"Eur J Med Res"},{"key":"4384_CR2","unstructured":"Global Burden of Disease (GBD). https:\/\/www.healthdata.org\/research-analysis\/gbd. Accessed 22 Nov 2023."},{"key":"4384_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631\u201349. https:\/\/doi.org\/10.1016\/j.ncl.2019.06.001.","journal-title":"Neurol Clin"},{"key":"4384_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470\u201385. https:\/\/doi.org\/10.1177\/0333102416678382.","journal-title":"Cephalalgia"},{"key":"4384_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, Paemeleire K, Reuter U, MaassenVanDenBrink A. Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet. 2025;405:1014\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(25)00109-6.","journal-title":"Lancet"},{"key":"4384_CR6","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383:1866\u201376. https:\/\/doi.org\/10.1056\/NEJMra1915327.","journal-title":"N Engl J Med"},{"key":"4384_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/ana.410160202","volume":"16","author":"MA Moskowitz","year":"1984","unstructured":"Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984;16:157\u201368. https:\/\/doi.org\/10.1002\/ana.410160202","journal-title":"Ann Neurol"},{"key":"4384_CR8","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev. 2023;103:1565\u2013644. https:\/\/doi.org\/10.1152\/physrev.00059.2021.","journal-title":"Physiol Rev"},{"key":"4384_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154359","volume":"11","author":"GR Nissan","year":"2022","unstructured":"Nissan GR, Kim R, Cohen JM, et al. Reducing the burden of migraine: safety and efficacy of CGRP pathway-targeted preventive treatments. J Clin Med. 2022;11: 4359. https:\/\/doi.org\/10.3390\/jcm11154359.","journal-title":"J Clin Med"},{"issue":"3","key":"4384_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler E-M, Puledda F, et al. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia. 2023;43(3): 3331024231152169. https:\/\/doi.org\/10.1177\/03331024231152169.","journal-title":"Cephalalgia"},{"key":"4384_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241305381","volume":"45","author":"R Ornello","year":"2025","unstructured":"Ornello R, Caponnetto V, Ahmed F, et al. Evidence-based guidelines for the pharmacological treatment of migraine. Cephalalgia. 2025;45: 3331024241305381. https:\/\/doi.org\/10.1177\/03331024241305381.","journal-title":"Cephalalgia"},{"key":"4384_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17:501\u201314. https:\/\/doi.org\/10.1038\/s41582-021-00509-5.","journal-title":"Nat Rev Neurol"},{"key":"4384_CR13","unstructured":"Ministerio de Sanidad - Profesionales de la Salud - Buscador. situaci\u00f3n financiaci\u00f3n medicamentos. https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do. Accessed 26 Nov 2023."},{"key":"4384_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11236925","volume":"11","author":"I Domitrz","year":"2022","unstructured":"Domitrz I, Golicki D. Health-related quality of life in migraine: EQ-5D-5L-based study in routine clinical practice. J Clin Med. 2022;11: 6925. https:\/\/doi.org\/10.3390\/jcm11236925.","journal-title":"J Clin Med"},{"key":"4384_CR15","doi-asserted-by":"publisher","first-page":"033310242513206","DOI":"10.1177\/03331024251320608","volume":"45","author":"S Sacco","year":"2025","unstructured":"Sacco S, Ashina M, Diener H-C, et al. Setting higher standards for migraine prevention: A position statement of the International Headache Society. Cephalalgia. 2025;45:03331024251320608. https:\/\/doi.org\/10.1177\/03331024251320608.","journal-title":"Cephalalgia"},{"key":"4384_CR16","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1080\/03007995.2024.2427884","volume":"40","author":"OJ Varnado","year":"2024","unstructured":"Varnado OJ, Jackson J, Scharf L, et al. Patient-reported outcomes related to migraine burden among patients treated with standard-of-care preventive medications or calcitonin gene-related monoclonal antibodies: a united States and Europe cross-sectional survey. Curr Med Res Opin. 2024;40:2179\u201390. https:\/\/doi.org\/10.1080\/03007995.2024.2427884.","journal-title":"Curr Med Res Opin"},{"key":"4384_CR17","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1007\/s10072-024-07380-4","volume":"45","author":"C Rosignoli","year":"2024","unstructured":"Rosignoli C, Caponnetto V, Onofri A, et al. Monoclonal antibodies targeting the calcitonin gene-related peptide pathway improve the effectiveness of acute medication-a real-world study. Neurol Sci. 2024;45:3305\u201312. https:\/\/doi.org\/10.1007\/s10072-024-07380-4.","journal-title":"Neurol Sci"},{"key":"4384_CR18","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/ene.15761","volume":"30","author":"F di Schiano","year":"2023","unstructured":"di Schiano F, Bolchini M, Ceccardi G, et al. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor. Eur J Neurol. 2023;30:1764\u201373. https:\/\/doi.org\/10.1111\/ene.15761.","journal-title":"Eur J Neurol"},{"key":"4384_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s10194-021-01366-9","volume":"22","author":"A Alpuente","year":"2021","unstructured":"Alpuente A, Gallardo VJ, Caronna E, et al. In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. J Headache Pain. 2021;22:151. https:\/\/doi.org\/10.1186\/s10194-021-01366-9.","journal-title":"J Headache Pain"},{"key":"4384_CR20","doi-asserted-by":"publisher","unstructured":"Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a National panel study of chronic disease. Health Qual Life Outcomes. 2004;2(12). https:\/\/doi.org\/10.1186\/1477-7525-2-12. Those seeking information regarding or permission to use the TSQM are directed to https:\/\/www.iqvia.com\/TSQM.","DOI":"10.1186\/1477-7525-2-12"},{"issue":"5","key":"4384_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087.","journal-title":"Ann Med"},{"key":"4384_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the headache impact test (HIT-6\u2122) across episodic and chronic migraine. Cephalalgia. 2011;31:357\u201367. https:\/\/doi.org\/10.1177\/0333102410379890.","journal-title":"Cephalalgia"},{"key":"4384_CR23","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng Y-S, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708\u201315. https:\/\/doi.org\/10.1016\/j.jval.2012.02.008.","journal-title":"Value Health"},{"key":"4384_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/ane.13599","volume":"145","author":"A L\u00f3pez-Bravo","year":"2022","unstructured":"L\u00f3pez-Bravo A, Oliveros-Cid A, Sevillano-Orte L. Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: a real-life experience in migraine. Acta Neurol Scand. 2022;145:669\u201375. https:\/\/doi.org\/10.1111\/ane.13599.","journal-title":"Acta Neurol Scand"},{"key":"4384_CR25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/head.14913","volume":"65","author":"A L\u00f3pez-Bravo","year":"2025","unstructured":"L\u00f3pez-Bravo A, M\u00ednguez-Olaondo A, Nieves-Castellanos C, et al. Patient satisfaction with calcitonin gene-related peptide monoclonal antibodies in migraine: a multicenter prospective cohort study. Headache. 2025;65:994\u20131004. https:\/\/doi.org\/10.1111\/head.14913.","journal-title":"Headache"},{"key":"4384_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s10194-022-01515-8","volume":"23","author":"AR Gantenbein","year":"2022","unstructured":"Gantenbein AR, Agosti R, Kamm CP, et al. Swiss quality of life and healthcare impact assessment in a real-world erenumab treated migraine population (SQUARE study): interim results. J Headache Pain. 2022;23:142. https:\/\/doi.org\/10.1186\/s10194-022-01515-8.","journal-title":"J Headache Pain"},{"key":"4384_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104943","author":"R Ornello","year":"2024","unstructured":"Ornello R, Andreou AP, Matteis ED, et al. Resistant and refractory migraine: clinical presentation, pathophysiology, and management. eBioMedicine. 2024. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104943.","journal-title":"eBioMedicine"},{"key":"4384_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s10194-021-01368-7","volume":"22","author":"M Terhart","year":"2021","unstructured":"Terhart M, Mecklenburg J, Neeb L, et al. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain. 2021;22:158. https:\/\/doi.org\/10.1186\/s10194-021-01368-7.","journal-title":"J Headache Pain"},{"key":"4384_CR29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4.","journal-title":"Lancet"},{"key":"4384_CR30","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1212\/WNL.0000000000010000","volume":"95","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Cohen JM, Gandhi SK, et al. Effect of fremanezumab on quality of life and productivity in patients with chronic migraine. Neurology. 2020;95:e878\u201388. https:\/\/doi.org\/10.1212\/WNL.0000000000010000.","journal-title":"Neurology"},{"key":"4384_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00221-w","volume":"4","author":"JH Ford","year":"2020","unstructured":"Ford JH, Foster SA, Nichols RM, et al. A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe. J Patient-Rep Outcomes. 2020;4: 53. https:\/\/doi.org\/10.1186\/s41687-020-00221-w.","journal-title":"J Patient-Rep Outcomes"},{"key":"4384_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msksp.2023.102783","volume":"66","author":"GF Carvalho","year":"2023","unstructured":"Carvalho GF, Luedtke K, Bevilaqua-Grossi D. Balance disorders and migraine. Musculoskelet Sci Pract. 2023;66: 102783. https:\/\/doi.org\/10.1016\/j.msksp.2023.102783.","journal-title":"Musculoskelet Sci Pract"},{"key":"4384_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361\u201370. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x.","journal-title":"Acta Psychiatr Scand"},{"key":"4384_CR34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia. 2020;40:543\u201353. https:\/\/doi.org\/10.1177\/0333102420912726.","journal-title":"Cephalalgia"},{"key":"4384_CR35","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine. Neurology. 2020;95:e2487-99. https:\/\/doi.org\/10.1212\/WNL.0000000000010600.","journal-title":"Neurology"},{"key":"4384_CR36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12883-018-1193-2","volume":"18","author":"A Camporeale","year":"2018","unstructured":"Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18:188. https:\/\/doi.org\/10.1186\/s12883-018-1193-2.","journal-title":"BMC Neurol"},{"key":"4384_CR37","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/head.13946","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS, et al. Determining thresholds for meaningful change for the headache impact test (HIT-6) total and item\u2010specific scores in chronic migraine. Headache. 2020;60:2003\u201313. https:\/\/doi.org\/10.1111\/head.13946.","journal-title":"Headache"},{"key":"4384_CR38","doi-asserted-by":"publisher","first-page":"E187","DOI":"10.1503\/cmaj.221607","volume":"195","author":"V Tzankova","year":"2023","unstructured":"Tzankova V, Becker WJ, Chan TLH. Pharmacologic prevention of migraine. CMAJ Can Med Assoc J. 2023;195:E187\u201392. https:\/\/doi.org\/10.1503\/cmaj.221607.","journal-title":"CMAJ Can Med Assoc J"},{"key":"4384_CR39","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478\u201388. https:\/\/doi.org\/10.1177\/0333102414547138.","journal-title":"Cephalalgia"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04384-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:02:15Z","timestamp":1760486535000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04384-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4384"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04384-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee for Medicinal Research (CEIm) of Fundaci\u00f3 Privada Hospital Asil de Granollers and adhered to the requirements of Spain\u2019s Organic Law 3\/2018 on the Protection of Personal Data and Guarantee of Digital Rights, the Principles of the Declaration of Helsinki, and Good Clinical Practice guidelines. In accordance with Royal Decree 957\/2020, published on November 3, 2020, and the ethical principles governing medical research involving human subjects, the committee granted an exemption from obtaining informed consent, based on the study\u2019s significant social value, exclusive use of anonymized secondary data, no impact on routine clinical practice, and minimal risk to participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"418"}}